首页> 美国卫生研究院文献>BMC Cancer >Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

【2h】

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

机译：卡铂联合聚乙二醇化脂质体阿霉素作为卵巢癌患者一线化疗方案的每周3周安全性：MITO-2随机试验的初步结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned.

机译：背景MITO-2（卵巢癌多中心意大利试验）研究是一项随机III期试验，比较了在卵巢癌患者的一线化疗中卡铂加紫杉醇与卡铂加聚乙二醇化脂质体阿霉素的比较。由于使用的为期3周的实验时间表上公布的第一阶段数据很少，因此计划进行早期安全性分析。

著录项

期刊名称 BMC Cancer
作者
Sandro Pignata; Giovanni Scambia; Antonella Savarese; Enrico Breda; Paolo Scollo; Rocco De Vivo; Emanuela Rossi; Vittorio Gebbia; Donato Natale; Filomena Del Gaizo; Emanuele Naglieri; Antonella Ferro; Pietro Musso; Alfonso Maria DArco; Roberto Sorio; Carmela Pisano; Massimo Di Maio; Giuseppe Signoriello; Annalisa Annunziata; Francesco Perrone;
展开▼
作者单位

展开▼
年(卷),期 2006(6),-1
年度 2006
页码 202
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial [J] . Sandro Pignata, Giovanni Scambia, Antonella Savarese, BMC Cancer . 2006 ,第1期

机译：卡铂联合聚乙二醇化脂质体阿霉素作为卵巢癌患者一线化疗方案的每周3周时间表的安全性：MITO-2随机试验的初步结果
2. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. [J] . Pignata S, Scambia G, Ferrandina G, Journal of Clinical Oncology . 2011 ,第27期

机译：卡铂加紫杉醇与卡铂加聚乙二醇化脂质体阿霉素作为卵巢癌患者的一线治疗药物：MITO-2随机III期试验。
3. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. [J] . Pignata S, Scambia G, Savarese A, Oncology: International Journal of Cancer Research and Treatment . 2009 ,第1期

机译：卡铂和聚乙二醇化阿霉素脂质体治疗晚期卵巢癌：MITO-2 III期试验的初步活性结果。
4. COMPLEMENT ACTIVATION BY PEGYLATED LIPOSOMAL DOXORUBICIN (DOXIL~R) IN CANCER PATIENTS: ASSOCIATION WITH HYPERSENSITIVITY REACTIONS [C] . A. Chanan-Khan, J. Szebeni, L. Leibes, International symposium on controlled release of bioactive materials;Consumer diversified products conference . 2001

机译：聚脂脂质体阿霉素（DOXIL〜R）在癌症患者中的补体激活：与超敏反应的关联
5. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
6. RANDOMIZED TRIAL OF PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) PLUS CARBOPLATIN VERSUS CARBOPLATIN IN PLATINUM-SENSITIVE (PS) PATIENTS WITH RECURRENT EPITHELIAL OVARIAN OR PERITONEAL CARCINOMA AFTER FAILURE OF INITIAL PLATINUM-BASED CHEMOTHERAPY (SOUTH WEST ONCOLOGY GROUP PROTOCOL S0200) [O] . David S. Alberts, P. Y. Liu, Sharon P. Wilczynski, -1

机译：在华氏200度以上的初始白热病患者（最初的化疗）后复发性上皮性卵巢或腹膜癌的铂敏感性（PS）患者中聚脂脂质体阿霉素（PLD）加卡铂与卡铂的随机对照试验
7. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial [O] . 2006

机译：卡铂联合聚乙二醇化脂质体多柔比星作为卵巢癌患者一线化疗的每周3周时间表的安全性：MITO-2随机试验的初步结果

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

摘要

著录项

相似文献

相关主题

期刊订阅